Ali Nouran Abdelmageed, Morsi Nadia M, Badr-Eldin Shaimaa M, Shamma Rehab N
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo university, Jeddah, Egypt.
Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
Front Bioeng Biotechnol. 2024 Oct 28;12:1439085. doi: 10.3389/fbioe.2024.1439085. eCollection 2024.
Osteoarthritis (OA) is regarded as one of the most prevealent irreversible joint degenerative disorder worldwide. Recently, considerable interest in utilizing intra-articular (IA) injections for managing OA has been raised.
In this study, IA injectable surface modified iron oxide microparticles (SMIOMPs) loaded with Diacerein (DCN) were developed. The effects of formulation parameters on particle size, entrapment efficiency, and zeta potential were explored using factorial design. The optimized formulation was characterized regarding morphology and in vitro release. Differential scanning calorimetry (DSC) and Fourier-transform infrared spectroscopy (FTIR) were done to assess interactions. Further, sterilization and performance in rats with induced arthritis has been performed for the optimized formulation.
The selected optimized system included 2M FeCL3 and 1% chitosan as a surface modifier achieved high drug entrapment of 85.25% with a PS of 1.54 µm and sustained DCN release. Morphological examination of the optimized formulation revealed spherical particles with chitosan coat. DSC and FTIR results indicated the absence of undesired interactions between DCN and the used components. No significant change in the measured parameters was observed following sterilization using gamma radiation. assessment revealed superior performance for the optimized formulation in reducing cartilage inflammation and degradation. Plasma levels of tumor necrosis factor α and Interleukin-1 beta, as well as knee diameter, were significantly reduced in the treated groups compared to the untreated ones.
Overall, the results suggest that the proposed DCN-loaded SMIOMPs represent a promising advancement in the arena of cartilage regeneration.
骨关节炎(OA)被认为是全球最常见的不可逆关节退行性疾病之一。最近,人们对利用关节内(IA)注射来治疗OA产生了浓厚兴趣。
在本研究中,开发了负载双醋瑞因(DCN)的可关节内注射的表面改性氧化铁微粒(SMIOMPs)。使用析因设计探索配方参数对粒径、包封率和zeta电位的影响。对优化后的配方进行了形态学和体外释放表征。采用差示扫描量热法(DSC)和傅里叶变换红外光谱法(FTIR)评估相互作用。此外,对优化后的配方进行了灭菌处理,并在诱导性关节炎大鼠中进行了性能测试。
所选的优化系统包括2M FeCL3和1%壳聚糖作为表面改性剂,实现了85.25%的高药物包封率,粒径为1.54 µm,并实现了DCN的持续释放。优化配方的形态学检查显示为带有壳聚糖涂层的球形颗粒。DSC和FTIR结果表明DCN与所用成分之间不存在不良相互作用。使用γ射线灭菌后,所测参数未观察到显著变化。评估显示优化后的配方在减轻软骨炎症和降解方面具有优异性能。与未治疗组相比,治疗组的肿瘤坏死因子α和白细胞介素-1β的血浆水平以及膝关节直径均显著降低。
总体而言,结果表明所提出的负载DCN的SMIOMPs在软骨再生领域代表了一项有前景的进展。